Accord BioPharma

We see things from the patients' perspective and believe what comes before and after a drug is just as important as the drug itself. We go #BeyondBiology

[Accord BioPharma @AccordBioPharma]

IMULDOSA® (ustekinumab-srlf) gains preferred coverage with Cigna across both pharmacy & medical benefits, expanding access for patients. Effective 4/15/26. Read more: https://t.co/NXfmGuoDvs

#Biosimilars #PatientAccess

[Accord BioPharma @AccordBioPharma]

#Breaking: We're proud to share that the @US_FDA has approved our #biosimilar FILKRI™ (filgrastim-laha), marking the sixth addition to our growing biosimilar portfolio and reinforcing our mission to expand our portfolio of more affordable treatment options. Learn more: https://t.co/NRUojHt3B2

[Accord BioPharma @AccordBioPharma]

HERCESSI™ (trastuzumab-strf) has been added to a major national preferred formulary, advancing our commitment to innovative approaches that strengthen treatment access for U.S. patients. Read the full announcement: https://t.co/tuABumxUlI #BiosimilarAccess

[Accord BioPharma @AccordBioPharma]

For some men with prostate cancer, hormone therapy may become an important part of the treatment journey. Understanding how it works, and what to expect can help patients feel more prepared and empowered throughout their journey. Learn more: https://t.co/Cf8QM0vY2B

[Accord BioPharma @AccordBioPharma]

Hearing you have #ProstateCancer may be overwhelming, but you're not alone. Finding a specialized healthcare team can provide the support to help guide your journey. Discover more about navigating prostate cancer management: https://t.co/Cf8QM0wvS9

[Accord BioPharma @AccordBioPharma]

Express Scripts has added IMULDOSA® (ustekinumab-srlf) to their national preferred formularies, expanding access for millions of patients in the U.S. Read the full announcement: https://t.co/I7qA3E0uWN #BeyondBiology

[Accord BioPharma @AccordBioPharma]

We’re proud to announce that our fourth and fifth biosimilars have received FDA approval. Learn more about how these approvals bring expanded, cost-effective treatment options to patients managing bone-related conditions: https://t.co/YaClRtn8Jg

#BeyondBiology #Biosimilars

[Accord BioPharma @AccordBioPharma]

#ProstateCancer screening doesn't have to be confusing. Know your risk factors. Ask the right questions. Make informed decisions about your health. Learn more about the facts of prostate cancer: https://t.co/AZSJLww22w

[Accord BioPharma @AccordBioPharma]

What if more patients could access the biologics they need? That's the promise of biosimilars—maintaining the same safety and efficacy while removing cost barriers. We're going #BeyondBiology to reimagine healthcare where quality treatment isn't limited by price.

[Accord BioPharma @AccordBioPharma]

At Accord, our greatest strength is our passionate people. What makes our team excited to work here? Our Key Account Managers share what draws them to Accord and keeps them inspired in their roles. #TeamAccord #EmployeeVoices #AccordBioPharma

[Accord BioPharma @AccordBioPharma]

Understanding treatment options like hormone therapy is important when navigating #ProstateCancer. We've partnered with @ZEROCancer to develop a discussion guide that empowers patients to have informed conversations and advocate for their care: https://t.co/Xya3OdXyWV #BeyondBiology

[Accord BioPharma @AccordBioPharma]

This #ProstateCancerAwarenessMonth, join us in raising awareness about one of the most common cancers in American men. At Accord, we're committed to making care more accessible and affordable for the #ProstateCancer community. #MensHealth

[Accord BioPharma @AccordBioPharma]

September kicks off @ZEROCancer walks nationwide, and we're proud to support our partners in this vital mission. Find a race near you: https://t.co/aJB8BPA4xa

#ZEROProstateCancer #ZERORunWalk #AccordCares

[Accord BioPharma @AccordBioPharma]

At Accord, we work across #Oncology, #Immunology, & #CriticalCare to reimagine therapies to support evolving patient needs. Our pipeline is designed with real patient experiences at the center—going #BeyondBiology to enhance care.

Learn more: https://t.co/0Ce9BkFdkO

[Accord BioPharma @AccordBioPharma]

Proud to announce the commercial launch of IMULDOSA® (ustekinumab-srlf), our third biosimilar to market! IMULDOSA represents our commitment to delivering high-quality, more cost-effective alternatives for critical conditions – because every patient deserves options. Read more: https://t.co/lknIOcfTK9 #BeyondBiology

[Accord BioPharma @AccordBioPharma]

We're leading the way to potentially life-changing therapies by bringing #biosimilars—cost-effective, highly similar versions of biologic drugs with no clinically meaningful differences in efficacy or safety—to the U.S. market. Learn more: https://t.co/NsgqZq4ZJ5

[Accord BioPharma @AccordBioPharma]

August is World Cancer Support Month. At Accord BioPharma, our oncology work is deeply personal as many of us have walked this journey with loved ones. Cancer affects entire communities, and we stand with everyone touched by it. #WorldCancerSupportMonth #AccordCares

[Accord BioPharma @AccordBioPharma]

For 7+ years, our Executive Assistant, Tanya Edwards, has volunteered with The Sisters Inspiring Sisters to help transport cancer patients and survivors for their treatment. We're proud to have team members who are dedicated to making a difference. #TeamAccord #BeyondBiology